Nothing Special   »   [go: up one dir, main page]

MXPA00006605A - Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. - Google Patents

Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.

Info

Publication number
MXPA00006605A
MXPA00006605A MXPA00006605A MXPA00006605A MXPA00006605A MX PA00006605 A MXPA00006605 A MX PA00006605A MX PA00006605 A MXPA00006605 A MX PA00006605A MX PA00006605 A MXPA00006605 A MX PA00006605A MX PA00006605 A MXPA00006605 A MX PA00006605A
Authority
MX
Mexico
Prior art keywords
alkyl
halo
substituted
alkoxy
inflammatory
Prior art date
Application number
MXPA00006605A
Other languages
English (en)
Inventor
Hayashi Shigeo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA00006605A publication Critical patent/MXPA00006605A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion provee un compuesto de la formula siguiente: (ver formula) (I) o las sales farmaceuticamente aceptables del mismo, en la cual A es alquileno C1-6 o -NR1-; Z es C(=L)R2, o SO2R3; U es CH o N; W e Y estan seleccionados, independientemente, de -CH2-, O, S y -N-R1; m es 1, 2 o 3; q y r son, independientemente, 0, 1 o 2; X esta seleccionado, independientemente, de halogeno, alquilo C1-4, alquilo C1-4 sustituido con halo, hidroxi, alcoxi C1-4, alcoxi C1-4 sustituido con halo o similares; n es 1 o 2; L es oxigeno o azufre; R1 es hidrogeno o alquilo C1-4; R2 es hidroxi, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, cicloalcoxi C3-7, (alquil C1-4)-(cicloalcoxi C3-7), -NR4R5 o similares; R3 es alquilo C1-6 sustituido con halo; y R4 y R5 estan seleccionados, independientemente, de hidrogeno, alquilo C1-6, y alquilo C1-6 sustituido con halo; esta invencion proporciona tambien una composicion farmaceutica util para el tratamiento de un estado medico en el cual esten implicadas prostaglandinas como patogenos.
MXPA00006605A 1999-07-02 1999-07-02 Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. MXPA00006605A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB99/01243 1999-07-02

Publications (1)

Publication Number Publication Date
MXPA00006605A true MXPA00006605A (es) 2004-12-09

Family

ID=11004872

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00006605A MXPA00006605A (es) 1999-07-02 1999-07-02 Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.

Country Status (11)

Country Link
US (1) US6303628B1 (es)
EP (1) EP1065204B1 (es)
JP (1) JP3333179B2 (es)
AT (1) ATE215945T1 (es)
BR (1) BR0002936A (es)
CA (1) CA2313122C (es)
DE (1) DE60000120T2 (es)
DK (1) DK1065204T3 (es)
ES (1) ES2173846T3 (es)
MX (1) MXPA00006605A (es)
PT (1) PT1065204E (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
EP1438289B1 (en) * 2001-09-27 2005-03-30 F. Hoffmann-La Roche AG Indole derivatives as cox ii inhibitors
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
MXPA04010186A (es) * 2002-04-18 2005-02-03 Pharmacia Corp Monoterapia para el tratamiento de la enfermedad de parkinson con inhibidor (es) de la ciclooxigenasa-2 (cox 2).
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ATE465725T1 (de) 2002-12-13 2010-05-15 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2509881A1 (en) * 2002-12-19 2004-07-08 Elan Pharmaceuticals, Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
WO2005079808A1 (en) 2004-01-22 2005-09-01 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CA2607913C (en) * 2005-05-05 2014-03-18 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
MX2009006575A (es) 2006-12-22 2009-07-02 Recordati Ireland Ltd Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
AR090835A1 (es) 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de quinazolindiona
US9695118B2 (en) 2012-04-24 2017-07-04 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
KR20160073413A (ko) 2013-10-23 2016-06-24 추가이 세이야쿠 가부시키가이샤 퀴나졸리논 및 이소퀴놀리논 유도체
EP3233797B1 (en) * 2015-01-18 2019-05-08 SRI International Inc. Map4k4 (hgk) inhibitors
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
AU717422B2 (en) 1995-09-01 2000-03-23 Eli Lilly And Company Indolyl neuropeptide Y receptor antagonists
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.

Also Published As

Publication number Publication date
CA2313122C (en) 2004-08-24
JP3333179B2 (ja) 2002-10-07
ATE215945T1 (de) 2002-04-15
BR0002936A (pt) 2001-04-03
CA2313122A1 (en) 2001-01-02
EP1065204A4 (en) 2000-11-15
PT1065204E (pt) 2002-08-30
ES2173846T3 (es) 2002-11-01
DE60000120T2 (de) 2002-08-14
EP1065204A1 (en) 2001-01-03
DE60000120D1 (de) 2002-05-16
JP2001031677A (ja) 2001-02-06
DK1065204T3 (da) 2002-07-22
US6303628B1 (en) 2001-10-16
EP1065204B1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
MXPA00006605A (es) Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
AP9801302A0 (en) Indole compounds as anti-inflammatory/analgesic agents..
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
IS7170A (is) Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra
AP2001002299A0 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
NZ518144A (en) Piperazine Compounds
SE9904508D0 (sv) New compounds
DE60107395D1 (de) 1,5-benzothiazepine und ihre verwendungs als hypolipidämika
PT928788E (pt) Compostos farmaceuticamente activos
NO166129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler.
IL107961A0 (en) Phenoxy- and phenoxyalkyl-piperidines and pharmaceutical compositions containing them
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
NO961077L (no) Substituerte benzoltienylpiperaziner, deres anvendelse som medikamenter og fremgangsmåter for fremstilling
MXPA00012398A (es) Compuestos de 1,4-dihidropiridina sustituidos con un heteroarilo de 5 miembros como antagonistas de la bradiquinina.
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
MY133207A (en) Substituted benzolactam compaunds
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
NZ504299A (en) 1-aza-2-alkyl-6-aryl-cycloalkane compounds, a process for their preparation and pharmaceutical compositions containing them
GB0121874D0 (en) Therapeutic agents
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana
TW200509936A (en) Pharmaceutical composition comprising a pyrrolopyridazine compound
ES2182755T3 (es) Compuestos de tetrazolilalquilindol como agentes antiinflamtorios y analgesicos.
MX9703074A (es) Inhibidores de sintesis de apoliproteina-b.

Legal Events

Date Code Title Description
FG Grant or registration